News & Analysis as of October 19, 2024

Biotechnology

+ Follow

The European Union is an economic and political partnership comprised of 27 nations within the Eurozone. The EU was established in 1948 to promote stability and cooperation among member states in the aftermath of WWII. The EU maintains a common currency as well as several intranational institutions, including the European Parliament and the European Commission. less -

[Event] Pharma & Biotech Patent Litigation Conference in Europe - May 29th - 30th, Amsterdam, Netherlands

American Conference Institute (ACI) on 3/25/2024

Hosted by C5 Group, the 17th Annual Forum on Pharma & Biotech Patent Litigation in Europe returns for another exciting year with curated programming that will provide up-to-the-minute information and strategic insights on...more

European Biologics Regulatory Updates

Goodwin on 11/21/2023

Bayer’s aflibercept 8 mg recommended for approval in Europe: On November 10, 2023, Bayer announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive...more

EU Study Shows Startups with IP 1000% More Likely to Be Funded

AEON Law on 10/31/2023

The European Patent Office (EPO) and the European Union Intellectual Property Office (EUIPO) have released a 61-page study showing that EU startups that secure intellectual property (IP) rights protection are 10.2 times more...more

[Event] 21st Annual Life Sciences IP Summit - September 27th - 28th, Munich, Germany

American Conference Institute (ACI) on 8/16/2023

Hosted by C5 Group, the 21st Annual Life Sciences IP Summit returns for another exciting year with curated programming with speakers from the pharma, biotech and medical device industries that will provide practical insights...more

[Event] C5’s 16th Annual Forum on Pharma & Biotech Patent Litigation in Europe - May 23rd - 24th, Amsterdam, Netherlands

American Conference Institute (ACI) on 4/10/2023

Hosted by C5, the 16th Annual Forum on Pharma & Biotech Patent Litigation in Europe returns 23-24 May, at the DoubleTree by Hilton Amsterdam Central Station, Amsterdam with curated programing for you to gain the knowledge and...more

Intellectual Property & Health | News To Know – June 2022

McDermott Will & Emery on 6/27/2022

RUSSIA RESPONDS TO WESTERN SANCTIONS WITH PATENT RETALIATION - On March 6, 2022, the Russian government retaliated against the West’s imposition of sanctions by issuing a decree permitting patented innovations to be used...more

Is your CTGT patent portfolio ready for the UPC?

Hogan Lovells on 5/27/2022

The introduction of the Unitary Patent and the corresponding Unified Patent Court (UPC) system is set to transform the patent litigation landscape in the European Union (EU). The potential impact on the business success of...more

Preparing for Europe’s Unified Patent Court

Proskauer - Life Sciences on 2/10/2022

After years of contemplation and delays, Europe’s Unified Patent Court will be operational in about one year. U.S.-based Life Sciences patent applicants should start preparing now to ensure that their applications withstand...more

A Dynamic Reversal by the EPO's Enlarged Board of Appeal

Jones Day on 5/26/2020

The Enlarged Board of Appeal of the European Patent Office has decided that the exclusion from patentability of essentially biological processes for the production of plants or animals now also extends to plant or animal...more

European SPC Manufacturing Waiver Goes into Force

McDermott Will & Emery on 7/12/2019

Newly issued EU Regulation 2019/933 provides supplementary protection certificate exemptions for exporting and stockpiling active pharmaceutical ingredients and medicinal products if certain anti-abuse requirements are met....more

Brexit: the impact on supplementary protection certificates (SPCs)

Hogan Lovells on 3/18/2019

On 6 February 2019 the House of Commons and House of Lords approved The Patents (Amendment) (EU Exit) Regulations 2018 (Patent SI), which, if it is signed into law, will come into force on Brexit day (i.e. 29 March 2019 or...more

[Event] 11th Pharma & Biotech Patent Litigation - February 26 - 27, 2019 - Radisson Blu Hotel, Amsterdam

American Conference Institute (ACI) on 1/4/2019

The annual gathering exploring the inherently complex and continually contentious pharma and biotech patent litigation - Life Science patent litigation filings are predicted to rise at new levels. Be part of the only event...more

Cyberdyne Bringing HAL Cyborg Exoskeleton to US Market

Knobbe Martens on 6/12/2018

Cyberdyne, a Japan-based robotics technology company, recently announced its collaboration with Brooks Rehabilitation and the Brooks Cybernic Treatment Center to bring its Hybrid Assistive Limb (HAL®) exoskeleton to the U.S....more

Patent law in Europe: What pharmaceutical companies need to know

Hogan Lovells on 5/18/2018

Increasing competition within Europe’s pharmaceutical space makes knowing the market and understanding available patent protections more critical than ever for both well established and new market players. Andreas von Falck...more

Brexit Bill - Impact on patents

Hogan Lovells on 11/15/2017

The UK government’s draft EU Withdrawal Bill (the “Brexit Bill“) aims to incorporate EU directives and regulations into UK domestic law in their current form immediately following Brexit (“Retained EU Law“). This article...more

Clarifying or Conforming? The EPO Bows to the European Commission

Jones Day on 7/17/2017

In December, we reported that the European Commission ("Commission") had issued an Interpretive Notice (2016/C 411/03) stating products produced by essentially biological processes should not be patentable. The notice came as...more

Global Patent Prosecution Newsletter - June 2017

Sterne, Kessler, Goldstein & Fox P.L.L.C. on 6/19/2017

Revocation Proceedings Around the World - Mechanisms to challenge the validity of granted patents are available in many countries throughout the world. The June 2017 issue of Sterne Kessler’s Global Patent Prosecution...more

Biotechnology Considerations for the Unitary Patent System in Light of Brexit and Other Current Developments

Knobbe Martens on 2/9/2017

Written by Daniel A. Kamkar and Eric Furman, Ph.D. After the United Kingdom voted to leave the European Union, dubbed “Brexit” by the press, many have called into question whether the UK would ratify the Unitary Patent...more

EPO Stays Proceedings Over Patentability Of Plants And Animals

Foley & Lardner LLP on 1/3/2017

While the U.S. is still sorting out “natural products” jurisprudence under 35 USC § 101, the European Patent Office (EPO) is wrestling with the patentability of plants and animals, and has announced an immediate stay on all...more

Getting the Most from Biotech Patents in Europe Without Breaking the Bank: Selecting the Right Countries for Validation

Knobbe Martens on 10/31/2016

Once a European patent application has been granted, all patentees must then choose to validate the granted application in one or more European countries. Such a decision may have long-term business and legal consequences. ...more

Freedom to Utilize Genetic Resources? The Nagoya Protocol Two Years Later

WilmerHale on 10/13/2016

Two years ago today, the Nagoya Protocol on Access to Genetic Resources and the Fair and Equitable Sharing of Benefits from their Utilization to the Convention on Biological Diversity (“Protocol”) entered into international...more

Continental patents a la carte or prix fixe? Biotechnology considerations for the unitary patent in Europe

Knobbe Martens on 9/7/2016

Unitary patents in Europe - The European unitary patent and Unitary Patent Court (UPC) are slated to go into effect in early 2017. These monumental changes will have a significant impact on the ways patent rights are...more

Myriad: Comparing US Law with European, Japanese and Australian Law

Ladas & Parry LLP on 6/20/2013

The decision by the U.S. Supreme Court that isolated DNA having the same sequence as naturally-occurring DNA is not patentable subject matter is inconsistent with the position of the European Patent Office and Japanese law....more

News from Abroad: UK Court of Appeal Upholds Invalidity of Enantiomer Patent

McDonnell Boehnen Hulbert & Berghoff LLP on 4/1/2013

Originally published in WP Thompson & Co. on April 1, 2013. The "Obvious to Try" Test Is Overused in Assessing Obviousness - The UK Court of Appeal Decision in Novartis AG vs Generics (UK) Ltd (trading as United...more

24 Results

View per page

Page: of 1

European Union › Patents › Biotechnology

"My best business intelligence, in one easy email…"